Remission of a Primary, Recurrent Thoracic Ewing Sarcoma in a 74-year-old woman.

Askin’s tumor Ewing sarcoma adult Ewing Sarcoma extraosseous Ewing Sarcoma primary neuroectodermal tumor pulmonary Ewing Sarcoma thoracic Ewing Sarcoma

Journal

Rare tumors
ISSN: 2036-3605
Titre abrégé: Rare Tumors
Pays: England
ID NLM: 101526926

Informations de publication

Date de publication:
2022
Historique:
received: 04 12 2021
accepted: 14 06 2022
entrez: 11 7 2022
pubmed: 12 7 2022
medline: 12 7 2022
Statut: epublish

Résumé

Ewing sarcoma is a primitive neuroectodermal tumor which seldom presents with primary disease in people over age 40 and outside of the appendicular or axial skeleton. We examine a case of primary thoracic Ewing Sarcoma diagnosed initially by CT-guided biopsy in a woman at the age of 74 years. The disease progressed after initial combined modality therapy consisting of neoadjuvant chemotherapy, surgical resection, and adjuvant radiation therapy and two additional courses of multiagent chemotherapy. After relapse of her disease, subsequent second- and third-line systemic agents which included chemotherapy and targeted agents were given with disease stabilization achieved now over 30 months from initial diagnosis. To our knowledge, this is the first report of a primary pulmonary Ewing sarcoma diagnosed in a patient greater than 70 years of age in whom multiple remissions have been achieved with tolerable toxicities.

Identifiants

pubmed: 35813490
doi: 10.1177/20363613221110836
pii: 10.1177_20363613221110836
pmc: PMC9260570
doi:

Types de publication

Case Reports

Langues

eng

Pagination

20363613221110836

Informations de copyright

© The Author(s) 2022.

Déclaration de conflit d'intérêts

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Lancet Oncol. 2020 Mar;21(3):446-455
pubmed: 32078813
Cancer. 1989 Oct 1;64(7):1548-53
pubmed: 2776115
Onco Targets Ther. 2019 Mar 27;12:2279-2288
pubmed: 30988632
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):125-35
pubmed: 9747829
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Mol Cancer Ther. 2013 Jul;12(7):1322-31
pubmed: 23619301
Clin Oncol (R Coll Radiol). 2010 Jun;22(5):374-81
pubmed: 20466282
Ann Surg Oncol. 2012 Nov;19(12):3816-22
pubmed: 22739653
Mod Pathol. 2006 Jun;19(6):815-9
pubmed: 16557276
Rare Tumors. 2015 May 21;7(2):5992
pubmed: 26266019
Arch Bronconeumol. 2017 Nov;53(11):642-643
pubmed: 28499589
J Clin Oncol. 2000 Sep;18(17):3108-14
pubmed: 10963639
Nutrients. 2021 Dec 08;13(12):
pubmed: 34959948
N Engl J Med. 2003 Feb 20;348(8):694-701
pubmed: 12594313
Lancet Oncol. 2016 Dec;17(12):1732-1742
pubmed: 27751846
Acta Oncol. 2015 Jul;54(7):1063-4
pubmed: 25345493
Lancet Oncol. 2019 Jan;20(1):120-133
pubmed: 30477937
Intern Med. 2019 May 1;58(9):1335-1339
pubmed: 30626819
Nutrients. 2020 Jun 04;12(6):
pubmed: 32512833

Auteurs

Robert M Tungate (RM)

USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA.

Kristi Lara (K)

USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA.

Dakshesh Patel (D)

USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA.

Alexander Fedenko (A)

USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA.

James Hu (J)

USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA.

Classifications MeSH